Allarity Therapeutics FY2024 net loss $24.5M; cash $20.9M at year-end, ~$25M at Q1 2025

Allarity Therapeutics, Inc.

Net loss $24.5M for 2024 vs $11.9M in 2023, driven by $9.7M intangible impairment and $2.5M SEC settlement.
Cash and receivables $20.9M at Dec 31, 2024, and ~$25M at end of Q1 2025; expected to fund operations into 2027.
R&D expenses decreased to $6.1M from $7.1M; G&A expenses $11.4M (including SEC accrual).
Enrollment in Phase 2 ovarian cancer trial expected H1 2025; VA-funded SCLC combination trial enrollment Q2-Q3 2025.
Authorized $5M share repurchase program; ATM program fully utilized and concluded.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.